Recent Quotes (30 days)

You have no recent quotes
chg | %

Spectral Diagnostics Inc  

(Public, TSE:SDI)   Watch this stock  
Find more results for SDI
0.350
+0.030 (9.38%)
Delayed:   11:49AM EST
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.32 - 0.35
52 week 0.22 - 0.68
Open 0.32
Vol / Avg. 125,590.00/173,751.00
Mkt cap 62.91M
P/E     -
Div/yield     -
EPS -0.08
Shares 179.74M
Beta 1.43
Inst. own     -
Nov 13, 2014
Q3 2014 Spectral Diagnostics Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -312.91% -423.17%
Operating margin -312.91% -425.37%
EBITD margin - -415.94%
Return on average assets -92.57% -102.68%
Return on average equity -139.66% -138.99%
Employees 20 -
CDP Score - -

Address

135-2 The West Mall
TORONTO, ON M9C 1C2
Canada
+1-416-6263233 (Phone)
+1-416-6267383 (Fax)

Website links

Description

Spectral Diagnostics Inc. (Spectral) is focuses on the development and commercialization of a treatment for severe sepsis. The Company�s products include Endotoxin Activity Assay (EAA) and the Toraymyxin therapeutic (PMX) and Reagents. The Company also manufactures and sells certain proprietary reagents. Endotoxin Activity Assay has achieved United States Federal and Drug Administration (FDA), Health Canada and European CE clearance. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream and the Company is conducting a Phase III clinical trial for the treatment of severe sepsis and septic shock. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators.

Officers and directors

Anthony P. Bihl III Chairman of the Board
Age: 57
Paul M. Walker M.D., Ph.D. President, Chief Executive Officer, Director
Anthony Businskas Chief Financial Officer, Executive Vice President, Corporate Secretary
Guadagni Guadagni Vice President - Sales and Marketing
Debra M. Foster RN Vice President - Clinical Development
William C. Stevens Director
Guillermo A. Herrera Independent Director